Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey

Genetics and Molecular Research

Volumn 10, Issue 3, 2011, Pages 1999-2008

  Yilmaz, M B ^a   Pazarbasi, A ^a   Guzel, A I ^a   Kocaturk Sel, S ^a   Kasap, H ^a   Kasap, M ^a   Urunsak, I F ^a   Basaran, S ^a   Alptekin, D ^a   Demirhan, O ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

BMD; CYP17; CYP19; Estradiol; Osteoporosis; Polymorphism

Indexed keywords

ESTRADIOL; GENOMIC DNA; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BONE DENSITY; CASE CONTROL STUDY; CONTROLLED STUDY; CYP17 GENE; CYP19 GENE; ESTRADIOL BLOOD LEVEL; EXON; FEMALE; FEMUR NECK; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LUMBAR SPINE; OSTEOPOROSIS; POSTMENOPAUSE; PROMOTER REGION; SCORING SYSTEM; TESTOSTERONE BLOOD LEVEL; TURKEY (REPUBLIC);

AGED; AGED, 80 AND OVER; ANDROGENS; AROMATASE; BONE DENSITY; CASE-CONTROL STUDIES; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; FEMALE; FEMUR NECK; GENOTYPE; GONADAL STEROID HORMONES; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE; TURKEY;

EID: 80955166983     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/vol10-3gmr1204     Document Type: Article

References (26)

1. Berstein LM, Imyanitov EN, Gamajunova VB, Kovalevskij AJ, et al. (2002). CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett. 180: 47-53.
2. Bulun SE, Lin Z, Imir G, Amin S, et al. (2005). Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol. Rev. 57: 359-383.
3. Carbonell SS, Masi L, Marini F, Del Monte F, et al. (2005). Genetics and pharmacogenetics of osteoporosis. J. Endocrinol. Invest. 28: 2-7.
4. Compston J (2010). Osteoporosis: social and economic impact. Radiol. Clin. North Am. 48: 477-482.
5. Eriksson AL, Lorentzon M, Vandenput L, Labrie F, et al. (2009). Genetic variations in sex steroid-related genes as predictors of serum estrogen levels in men. J. Clin. Endocrinol. Metab. 94: 1033-1041.
6. Feigelson HS, McKean-Cowdin R and Henderson BE (2002). Concerning the CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17: 445-446.
7. Gennari L, Becherini L, Falchetti A, Masi L, et al. (2002). Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. J. Steroid Biochem. Mol. Biol. 81: 1-24.
8. Kado N, Kitawaki J, Obayashi H, Ishihara H, et al. (2002). Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women. Hum. Reprod. 17: 897-902.
9. Khosla S (2010). Update on estrogens and the skeleton. J. Clin. Endocrinol. Metab. 95: 3569-3577.
10. Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, et al. (2000). A TA repeat polymorphism in the estrogen receptor gene is associated with osteoporotic fractures but polymorphisms in the first exon and intron are not. J. Bone Miner. Res. 15: 2222-2230.
11. Lorentzon M, Swanson C, Eriksson AL, Mellstrom D, et al. (2006). Polymorphisms in the aromatase gene predict areal BMD as a result of affected cortical bone size: the GOOD study. J. Bone Miner. Res. 21: 332-339.
12. Masi L, Becherini L, Gennari L, Amedei A, et al. (2001). Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 86: 2263-2269.
13. Nelson LR and Bulun SE (2001). Estrogen production and action. J. Am. Acad. Dermatol. 45: S116-S124.
14. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, et al. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann. Oncol. 20: 1489-1498.
15. Ralston SH (2003). Genetic determinants of susceptibility to osteoporosis. Curr. Opin. Pharmacol. 3: 286-290.
16. Riancho JA, Zarrabeitia MT, Valero C, Sanudo C, et al. (2005). Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 36: 917-925.
17. Riggs BL, Khosla S and Melton LJ (2002). Sex steroids and the construction and conservation of the adult skeleton. Endocr. Rev. 23: 279-302.
18. Sharp L, Cardy AH, Cotton SC and Little J (2004). CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. a HuGE review. Am. J. Epidemiol. 160: 729-740.
19. Siegelmann-Danieli N and Buetow KH (1999). Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br. J. Cancer 79: 456-463.
20. Simpson ER (2000). Role of aromatase in sex steroid action. J. Mol. Endocrinol. 25: 149-156.
21. Sipos W, Pietschmann P, Rauner M, Kerschan-Schindl K, et al. (2009). Pathophysiology of osteoporosis. Wien. Med. Wochenschr. 159: 230-234.
22. Somner J, McLellan S, Cheung J, Mak YT, et al. (2004). Polymorphisms in the P450 c17 (17-hydroxylase/17,20-Lyase) and P450 c19 (aromatase) genes: association with serum sex steroid concentrations and bone mineral density in postmenopausal women. J. Clin. Endocrinol. Metab. 89: 344-351.
23. CL, Kindmark A, Brandstrom H, Abrahamsen B, et al. (2004). Polymorphisms in the CYP19 and AR genes -relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: the Danish osteoporosis prevention study. Calcif. Tissue Int. 74: 25-34.
24. Waltman NL, Ott CD, Twiss JJ, Gross GJ, et al. (2008). Bone mineral density and bone turnover in postmenopausal women treated for breast cancer. Cancer Nurs. 31: 182-190.
25. Ye Z and Parry JM (2002). The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 17: 119-126.
26. Zmuda JM, Cauley JA, Kuller LH and Ferrell RE (2001). A common promotor variant in the cytochrome P450c17alpha (CYP17) gene is associated with bioavailability testosterone levels and bone size in men. J. Bone Miner. Res. 16: 911-917.